Bladder cancer treatment combining two newer drugs
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new combination of two medications—one that targets HER2 on cancer cells and one that boosts your immune system—given directly into the bladder. It is for people with high-risk bladder cancer that hasn't spread into the muscle, and who haven't had BCG therapy or for whom BCG didn't work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had bladder surgery (TURBT) within the last 3 weeks to remove the tumor.
- Your tumor must have a certain protein called HER2 (levels 1+, 2+, or 3+). If it's 2+, a special test (FISH) is needed to confirm it.
- You are generally able to care for yourself (ECOG score 0-2).
- Your heart, blood, liver, and kidney function must be within a healthy range (checked by blood tests and an ultrasound of the heart).
- If you or your partner could become pregnant, you must agree to use effective birth control during the trial and for 6 months after.
- Your cancer must be non-muscle invasive (meaning it hasn't spread into the bladder muscle or elsewhere).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This study tests a new combination of an antibody-drug conjugate (a targeted therapy) with an immunotherapy drug, plus allergy and vitamin B12 medications, for advanced bladder cancer. It aims to see if this combo is safe and effective for people whose tumors have a certain marker called HER2.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This study tests whether a combination of two drugs can treat bladder cancer without needing to remove the bladder. It is for people whose cancer has not spread beyond the bladder and who prefer to avoid surgery.
This trial tests a new drug combination for advanced bladder or urinary tract cancer that has not been treated before. The study compares a standard chemotherapy plus immunotherapy with and without an extra drug that may reduce side effects.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.